Difference between revisions of "BRST5:Volunteer Assignments and Opportunities"
Jump to navigation
Jump to search
[checked revision] | [checked revision] |
Kgeiersbach (talk | contribs) |
|||
(27 intermediate revisions by 2 users not shown) | |||
Line 6: | Line 6: | ||
To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest. | To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest. | ||
− | + | __TOC__ | |
<br /> | <br /> | ||
{| class="wikitable" style="margin:auto" | {| class="wikitable" style="margin:auto" | ||
Line 19: | Line 19: | ||
!'''Notes''' | !'''Notes''' | ||
|- | |- | ||
− | |CHAPTER 2 (EPITHELIAL TUMOURS OF THE BREAST) | + | | |
+ | ====CHAPTER 2 (EPITHELIAL TUMOURS OF THE BREAST)==== | ||
| | | | ||
---- | ---- | ||
Line 39: | Line 40: | ||
---- | ---- | ||
|- | |- | ||
− | |Usual | + | |Usual ductal hyperplasia |
|Disease | |Disease | ||
| | | | ||
Line 50: | Line 51: | ||
| | | | ||
|- | |- | ||
− | |Columnar | + | |Columnar cell lesions, including flat epithelial atypia||Disease|| |
| | | | ||
| | | | ||
Line 59: | Line 60: | ||
| | | | ||
|- | |- | ||
− | |Atypical | + | |Atypical ductal hyperplasia||Disease|| |
| | | | ||
| | | | ||
Line 68: | Line 69: | ||
| | | | ||
|- | |- | ||
− | |Sclerosing | + | |Sclerosing adenosis||Disease|| |
| | | | ||
| | | | ||
Line 77: | Line 78: | ||
| | | | ||
|- | |- | ||
− | |Apocrine | + | |Apocrine adenosis and adenoma||Disease|| |
| | | | ||
| | | | ||
Line 86: | Line 87: | ||
| | | | ||
|- | |- | ||
− | |Microglandular | + | |Microglandular adenosis||Disease|| |
| | | | ||
| | | | ||
Line 95: | Line 96: | ||
| | | | ||
|- | |- | ||
− | |Radial | + | |Radial scar/complex sclerosing lesion||Disease|| |
| | | | ||
| | | | ||
Line 104: | Line 105: | ||
| | | | ||
|- | |- | ||
− | |Tubular | + | |Tubular adenoma||Disease|| |
| | | | ||
| | | | ||
Line 113: | Line 114: | ||
| | | | ||
|- | |- | ||
− | |Lactating | + | |Lactating adenoma||Disease|| |
| | | | ||
| | | | ||
Line 122: | Line 123: | ||
| | | | ||
|- | |- | ||
− | |Ductal | + | !'''Disease''' |
+ | !'''Page Type''' | ||
+ | !'''<span style="color:#0070C0">Author''' | ||
+ | !'''Date Assigned to Author''' | ||
+ | !'''Target Completion Date''' | ||
+ | !'''Author Content (Pending or Complete)''' | ||
+ | !'''Date Completed by Author''' | ||
+ | !'''Associate Editor''' | ||
+ | !'''Date of Last Editor Review''' | ||
+ | !'''Notes''' | ||
+ | |- | ||
+ | |Ductal adenoma||Disease|| | ||
| | | | ||
| | | | ||
Line 131: | Line 143: | ||
| | | | ||
|- | |- | ||
− | |Pleomorphic | + | |Pleomorphic adenoma||Disease|| |
| | | | ||
| | | | ||
Line 149: | Line 161: | ||
| | | | ||
|- | |- | ||
− | |Malignant | + | |Malignant adenomyoepithelioma||Disease|| |
| | | | ||
| | | | ||
Line 158: | Line 170: | ||
| | | | ||
|- | |- | ||
− | |Intraductal | + | |Intraductal papilloma||Disease|| |
| | | | ||
| | | | ||
Line 167: | Line 179: | ||
| | | | ||
|- | |- | ||
− | |Papillary | + | |Papillary ductal carcinoma in situ||Disease|| |
| | | | ||
| | | | ||
Line 176: | Line 188: | ||
| | | | ||
|- | |- | ||
− | |Encapsulated | + | |Encapsulated papillary carcinoma||Disease|| |
| | | | ||
| | | | ||
Line 185: | Line 197: | ||
| | | | ||
|- | |- | ||
− | |Solid | + | |Solid papillary carcinoma (in situ and invasive)||Disease|| |
| | | | ||
| | | | ||
Line 194: | Line 206: | ||
| | | | ||
|- | |- | ||
− | |Invasive | + | |Invasive papillary carcinoma||Disease|| |
| | | | ||
| | | | ||
Line 203: | Line 215: | ||
| | | | ||
|- | |- | ||
− | |Atypical | + | |Atypical lobular hyperplasia||Disease|| |
| | | | ||
| | | | ||
Line 212: | Line 224: | ||
| | | | ||
|- | |- | ||
− | |Lobular | + | !'''Disease''' |
+ | !'''Page Type''' | ||
+ | !'''<span style="color:#0070C0">Author''' | ||
+ | !'''Date Assigned to Author''' | ||
+ | !'''Target Completion Date''' | ||
+ | !'''Author Content (Pending or Complete)''' | ||
+ | !'''Date Completed by Author''' | ||
+ | !'''Associate Editor''' | ||
+ | !'''Date of Last Editor Review''' | ||
+ | !'''Notes''' | ||
+ | |- | ||
+ | |Lobular carcinoma in situ||Disease|| | ||
| | | | ||
| | | | ||
Line 221: | Line 244: | ||
| | | | ||
|- | |- | ||
− | |Ductal | + | |Ductal carcinoma in situ||Disease|| |
| | | | ||
| | | | ||
Line 230: | Line 253: | ||
| | | | ||
|- | |- | ||
− | |Invasive | + | |Invasive breast carcinoma of no special type||Disease|| |
| | | | ||
| | | | ||
Line 239: | Line 262: | ||
| | | | ||
|- | |- | ||
− | |Microinvasive | + | |Microinvasive carcinoma||Disease|| |
| | | | ||
| | | | ||
Line 248: | Line 271: | ||
| | | | ||
|- | |- | ||
− | |Invasive lobular | + | |Invasive lobular carcinoma||Disease|| |
| | | | ||
| | | | ||
Line 257: | Line 280: | ||
| | | | ||
|- | |- | ||
− | |Tubular | + | |Tubular carcinoma||Disease|| |
| | | | ||
| | | | ||
Line 266: | Line 289: | ||
| | | | ||
|- | |- | ||
− | |Cribriform | + | |Cribriform carcinoma||Disease|| |
| | | | ||
| | | | ||
Line 275: | Line 298: | ||
| | | | ||
|- | |- | ||
− | |Mucinous | + | |Mucinous carcinoma||Disease|| |
| | | | ||
| | | | ||
Line 284: | Line 307: | ||
| | | | ||
|- | |- | ||
− | |Mucinous | + | |Mucinous cystadenocarcinoma||Disease|| |
| | | | ||
| | | | ||
Line 293: | Line 316: | ||
| | | | ||
|- | |- | ||
− | |Invasive | + | |Invasive micropapillary carcinoma||Disease|| |
| | | | ||
| | | | ||
Line 302: | Line 325: | ||
| | | | ||
|- | |- | ||
− | |Carcinoma with | + | !'''Disease''' |
+ | !'''Page Type''' | ||
+ | !'''<span style="color:#0070C0">Author''' | ||
+ | !'''Date Assigned to Author''' | ||
+ | !'''Target Completion Date''' | ||
+ | !'''Author Content (Pending or Complete)''' | ||
+ | !'''Date Completed by Author''' | ||
+ | !'''Associate Editor''' | ||
+ | !'''Date of Last Editor Review''' | ||
+ | !'''Notes''' | ||
+ | |- | ||
+ | |Carcinoma with apocrine differentiation||Disease|| | ||
| | | | ||
| | | | ||
Line 311: | Line 345: | ||
| | | | ||
|- | |- | ||
− | |Metaplastic | + | |Metaplastic carcinoma||Disease|| |
| | | | ||
| | | | ||
Line 320: | Line 354: | ||
| | | | ||
|- | |- | ||
− | |Acinic | + | |[[BRST5:Acinic cell carcinoma|Acinic cell carcinoma]]||Disease||Patricija Zot |
|2/28/2024 | |2/28/2024 | ||
| | | | ||
Line 329: | Line 363: | ||
| | | | ||
|- | |- | ||
− | |[[Adenoid | + | |[[BRST5:Adenoid cystic carcinoma|Adenoid cystic carcinoma]]||Disease||Katherine Geiersbach / Jun Liao |
|10/12/02022 | |10/12/02022 | ||
|11/11/2023 | |11/11/2023 | ||
Line 338: | Line 372: | ||
|2021 template added | |2021 template added | ||
|- | |- | ||
− | |[[Secretory | + | |[[BRST5:Secretory carcinoma|Secretory carcinoma]]||Disease||Hui Chen / Morteza Seifi |
|10/12/2022 | |10/12/2022 | ||
|11/11/2023 | |11/11/2023 | ||
− | | | + | |COMPLETE |
| | | | ||
|Katherine Geiersbach | |Katherine Geiersbach | ||
Line 347: | Line 381: | ||
|2021 template added | |2021 template added | ||
|- | |- | ||
− | |Mucoepidermoid | + | |Mucoepidermoid carcinoma||Disease|| |
| | | | ||
| | | | ||
Line 356: | Line 390: | ||
| | | | ||
|- | |- | ||
− | |Polymorphous | + | |Polymorphous adenocarcinoma||Disease|| |
| | | | ||
| | | | ||
Line 365: | Line 399: | ||
| | | | ||
|- | |- | ||
− | |[[Tall | + | |[[BRST5:Tall cell carcinoma with reversed polarity|Tall cell carcinoma with reversed polarity]]||Disease||H. Evin Gulbahce |
|8/11/2023 | |8/11/2023 | ||
|10/11/2023 | |10/11/2023 | ||
Line 374: | Line 408: | ||
|2021 template added | |2021 template added | ||
|- | |- | ||
− | |Neuroendocrine | + | |Neuroendocrine tumour||Disease|| |
| | | | ||
| | | | ||
Line 383: | Line 417: | ||
| | | | ||
|- | |- | ||
− | |Neuroendocrine | + | |Neuroendocrine carcinoma||Disease|| |
| | | | ||
| | | | ||
Line 392: | Line 426: | ||
| | | | ||
|- | |- | ||
− | |CHAPTER 3 (FIBROEPITHELIAL TUMOURS AND HAMARTOMAS OF THE BREAST) | + | !'''Disease''' |
+ | !'''Page Type''' | ||
+ | !'''<span style="color:#0070C0">Author''' | ||
+ | !'''Date Assigned to Author''' | ||
+ | !'''Target Completion Date''' | ||
+ | !'''Author Content (Pending or Complete)''' | ||
+ | !'''Date Completed by Author''' | ||
+ | !'''Associate Editor''' | ||
+ | !'''Date of Last Editor Review''' | ||
+ | !'''Notes''' | ||
+ | |- | ||
+ | | | ||
+ | ====CHAPTER 3 (FIBROEPITHELIAL TUMOURS AND HAMARTOMAS OF THE BREAST)==== | ||
| | | | ||
---- | ---- | ||
Line 421: | Line 467: | ||
| | | | ||
|- | |- | ||
− | |[[Fibroadenoma]]||Disease||H. Evin Gulbahce / Patricija Zot | + | |[[BRST5:Fibroadenoma|Fibroadenoma]]||Disease||H. Evin Gulbahce / Patricija Zot |
|8/11/2023 | |8/11/2023 | ||
|11/11/2023 | |11/11/2023 | ||
Line 430: | Line 476: | ||
|2021 template added | |2021 template added | ||
|- | |- | ||
− | |[[Phyllodes | + | |[[BRST5:Phyllodes tumour|Phyllodes tumour]]||Disease||Emilie Lalonde / H. Evin Gulbahce /Katherine Geiersbach |
|8/11/2023 | |8/11/2023 | ||
|11/11/2023 | |11/11/2023 | ||
Line 439: | Line 485: | ||
|2021 template added | |2021 template added | ||
|- | |- | ||
− | |CHAPTER 4 (TUMOURS OF THE NIPPLE) | + | | |
+ | ====CHAPTER 4 (TUMOURS OF THE NIPPLE)==== | ||
| | | | ||
---- | ---- | ||
Line 459: | Line 506: | ||
---- | ---- | ||
|- | |- | ||
− | |Syringomatous | + | |Syringomatous tumour||Disease|| |
| | | | ||
| | | | ||
Line 468: | Line 515: | ||
| | | | ||
|- | |- | ||
− | |Nipple | + | |Nipple adenoma||Disease|| |
| | | | ||
| | | | ||
Line 477: | Line 524: | ||
| | | | ||
|- | |- | ||
− | |Paget disease of the | + | |Paget disease of the breast||Disease|| |
| | | | ||
| | | | ||
Line 486: | Line 533: | ||
| | | | ||
|- | |- | ||
− | |CHAPTER 5 (MESENCHYMAL TUMOURS OF THE BREAST) | + | | |
+ | ====CHAPTER 5 (MESENCHYMAL TUMOURS OF THE BREAST)==== | ||
| | | | ||
---- | ---- | ||
Line 514: | Line 562: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | !'''Disease''' | ||
+ | !'''Page Type''' | ||
+ | !'''<span style="color:#0070C0">Author''' | ||
+ | !'''Date Assigned to Author''' | ||
+ | !'''Target Completion Date''' | ||
+ | !'''Author Content (Pending or Complete)''' | ||
+ | !'''Date Completed by Author''' | ||
+ | !'''Associate Editor''' | ||
+ | !'''Date of Last Editor Review''' | ||
+ | !'''Notes''' | ||
|- | |- | ||
|Angiomatosis||Disease|| | |Angiomatosis||Disease|| | ||
Line 524: | Line 583: | ||
| | | | ||
|- | |- | ||
− | |Atypical | + | |Atypical vascular lesions||Disease|| |
| | | | ||
| | | | ||
Line 533: | Line 592: | ||
| | | | ||
|- | |- | ||
− | |Postradiation | + | |Postradiation angiosarcoma of the breast||Disease|| |
| | | | ||
| | | | ||
Line 542: | Line 601: | ||
| | | | ||
|- | |- | ||
− | |Primary | + | |Primary angiosarcoma of the breast||Disease|| |
| | | | ||
| | | | ||
Line 551: | Line 610: | ||
| | | | ||
|- | |- | ||
− | |Nodular | + | |Nodular fasciitis||Disease|| |
| | | | ||
| | | | ||
Line 569: | Line 628: | ||
| | | | ||
|- | |- | ||
− | |Desmoid | + | |Desmoid fibromatosis||Disease|| |
| | | | ||
| | | | ||
Line 578: | Line 637: | ||
| | | | ||
|- | |- | ||
− | |[[Inflammatory | + | |[[BRST5:Inflammatory myofibroblastic tumour|Inflammatory myofibroblastic tumour]]||Disease||Yajuan Liu |
|8/11/2023 | |8/11/2023 | ||
|11/11/2023 | |11/11/2023 | ||
Line 605: | Line 664: | ||
| | | | ||
|- | |- | ||
− | |Granular | + | !'''Disease''' |
+ | !'''Page Type''' | ||
+ | !'''<span style="color:#0070C0">Author''' | ||
+ | !'''Date Assigned to Author''' | ||
+ | !'''Target Completion Date''' | ||
+ | !'''Author Content (Pending or Complete)''' | ||
+ | !'''Date Completed by Author''' | ||
+ | !'''Associate Editor''' | ||
+ | !'''Date of Last Editor Review''' | ||
+ | !'''Notes''' | ||
+ | |- | ||
+ | |Granular cell tumour||Disease|| | ||
| | | | ||
| | | | ||
Line 659: | Line 729: | ||
| | | | ||
|- | |- | ||
− | |Pseudoangiomatous | + | |Pseudoangiomatous stromal hyperplasia||Disease|| |
| | | | ||
| | | | ||
Line 668: | Line 738: | ||
| | | | ||
|- | |- | ||
− | |CHAPTER 6 (HAEMATOLYMPHOID TUMOURS OF THE BREAST) | + | | |
+ | ====CHAPTER 6 (HAEMATOLYMPHOID TUMOURS OF THE BREAST)==== | ||
| | | | ||
---- | ---- | ||
Line 688: | Line 759: | ||
---- | ---- | ||
|- | |- | ||
− | |Extranodal | + | |Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)||Disease|| |
| | | | ||
| | | | ||
Line 697: | Line 768: | ||
| | | | ||
|- | |- | ||
− | |Follicular | + | |Follicular lymphoma||Disease|| |
| | | | ||
| | | | ||
Line 706: | Line 777: | ||
| | | | ||
|- | |- | ||
− | |Diffuse | + | !'''Disease''' |
+ | !'''Page Type''' | ||
+ | !'''<span style="color:#0070C0">Author''' | ||
+ | !'''Date Assigned to Author''' | ||
+ | !'''Target Completion Date''' | ||
+ | !'''Author Content (Pending or Complete)''' | ||
+ | !'''Date Completed by Author''' | ||
+ | !'''Associate Editor''' | ||
+ | !'''Date of Last Editor Review''' | ||
+ | !'''Notes''' | ||
+ | |- | ||
+ | |Diffuse large B-cell lymphoma||Disease|| | ||
| | | | ||
| | | | ||
Line 715: | Line 797: | ||
| | | | ||
|- | |- | ||
− | |Burkitt | + | |Burkitt lymphoma||Disease|| |
| | | | ||
| | | | ||
Line 724: | Line 806: | ||
| | | | ||
|- | |- | ||
− | |Breast | + | |Breast implant-associated anaplastic large cell lymphoma||Disease|| |
| | | | ||
| | | | ||
Line 733: | Line 815: | ||
| | | | ||
|- | |- | ||
− | |CHAPTER 7 (TUMOURS OF THE MALE BREAST) | + | | |
+ | ====CHAPTER 7 (TUMOURS OF THE MALE BREAST)==== | ||
| | | | ||
---- | ---- | ||
Line 762: | Line 845: | ||
| | | | ||
|- | |- | ||
− | |Carcinoma | + | |Carcinoma in situ||Disease|| |
| | | | ||
| | | | ||
Line 771: | Line 854: | ||
| | | | ||
|- | |- | ||
− | |Invasive | + | |Invasive carcinoma||Disease|| |
| | | | ||
| | | | ||
Line 780: | Line 863: | ||
| | | | ||
|- | |- | ||
− | |Metastases to the | + | |Metastases to the breast||Disease|| |
| | | | ||
| | | | ||
Line 789: | Line 872: | ||
| | | | ||
|- | |- | ||
− | |CHAPTER 8 (GENETIC TUMOUR SYNDROMES OF THE BREAST) | + | | |
+ | ====CHAPTER 8 (GENETIC TUMOUR SYNDROMES OF THE BREAST)==== | ||
| | | | ||
---- | ---- | ||
Line 809: | Line 893: | ||
---- | ---- | ||
|- | |- | ||
− | |BRCA1/2- | + | |[[BRST5:BRCA1/2-associated hereditary breast and ovarian cancer syndrome|BRCA1/2-associated hereditary breast and ovarian cancer syndrome]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
+ | |- | ||
+ | !'''Disease''' | ||
+ | !'''Page Type''' | ||
+ | !'''<span style="color:#0070C0">Author''' | ||
+ | !'''Date Assigned to Author''' | ||
+ | !'''Target Completion Date''' | ||
+ | !'''Author Content (Pending or Complete)''' | ||
+ | !'''Date Completed by Author''' | ||
+ | !'''Associate Editor''' | ||
+ | !'''Date of Last Editor Review''' | ||
+ | !'''Notes''' | ||
|- | |- | ||
− | |Cowden | + | |[[BRST5:Cowden syndrome|Cowden syndrome]]||Disease||[[DIG5:Volunteer Assignments and Opportunities|See DIG5 volunteer sheet for authorship status]] |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
|- | |- | ||
− | |Ataxia- | + | |[[BRST5:Ataxia-telangiectasia|Ataxia-telangiectasia]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
|- | |- | ||
− | |Li-Fraumeni | + | |[[BRST5:Li-Fraumeni syndrome, TP53-associated|Li-Fraumeni syndrome, TP53-associated]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
|- | |- | ||
− | |Li-Fraumeni | + | |[[BRST5:Li-Fraumeni syndrome, CHEK2-associated|Li-Fraumeni syndrome, CHEK2-associated]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
|- | |- | ||
− | |CDH1- | + | |[[BRST5:CDH1-associated breast cancer|CDH1-associated breast cancer]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
|- | |- | ||
− | |PALB2- | + | |[[BRST5:PALB2-associated cancers|PALB2-associated cancers]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
|- | |- | ||
− | |Peutz-Jeghers | + | |[[BRST5:Peutz-Jeghers syndrome|Peutz-Jeghers syndrome]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
|- | |- | ||
− | |Neurofibromatosis | + | |[[GTS5:Neurofibromatosis type 1 (NF1)|Neurofibromatosis type 1]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
|- | |- | ||
− | |[[Polygenic | + | |[[BRST5:Polygenic component of breast cancer susceptibility|Polygenic component of breast cancer susceptibility]] |
|Disease | |Disease | ||
+ | |Xiaolin Hu | ||
+ | |6/4/2024 | ||
| | | | ||
| | | | ||
Line 897: | Line 994: | ||
| | | | ||
| | | | ||
− | + | |Template added (6/4/24) | |
− | |||
− | |Template added ( | ||
|- | |- | ||
|}<br /> | |}<br /> |
Latest revision as of 13:52, 10 September 2024
Welcome!
For assignments, please see the "Author" column below (highlighted blue).
If empty (no name is present), please volunteer to create content for that disease!
To volunteer, please [Contact us] with your page of interest.
Disease | Page Type | Author | Date Assigned to Author | Target Completion Date | Author Content (Pending or Complete) | Date Completed by Author | Associate Editor | Date of Last Editor Review | Notes |
---|---|---|---|---|---|---|---|---|---|
CHAPTER 2 (EPITHELIAL TUMOURS OF THE BREAST) |
|
|
|
|
|
|
|
|
|
Usual ductal hyperplasia | Disease | ||||||||
Columnar cell lesions, including flat epithelial atypia | Disease | ||||||||
Atypical ductal hyperplasia | Disease | ||||||||
Sclerosing adenosis | Disease | ||||||||
Apocrine adenosis and adenoma | Disease | ||||||||
Microglandular adenosis | Disease | ||||||||
Radial scar/complex sclerosing lesion | Disease | ||||||||
Tubular adenoma | Disease | ||||||||
Lactating adenoma | Disease | ||||||||
Disease | Page Type | Author | Date Assigned to Author | Target Completion Date | Author Content (Pending or Complete) | Date Completed by Author | Associate Editor | Date of Last Editor Review | Notes |
Ductal adenoma | Disease | ||||||||
Pleomorphic adenoma | Disease | ||||||||
Adenomyoepithelioma | Disease | ||||||||
Malignant adenomyoepithelioma | Disease | ||||||||
Intraductal papilloma | Disease | ||||||||
Papillary ductal carcinoma in situ | Disease | ||||||||
Encapsulated papillary carcinoma | Disease | ||||||||
Solid papillary carcinoma (in situ and invasive) | Disease | ||||||||
Invasive papillary carcinoma | Disease | ||||||||
Atypical lobular hyperplasia | Disease | ||||||||
Disease | Page Type | Author | Date Assigned to Author | Target Completion Date | Author Content (Pending or Complete) | Date Completed by Author | Associate Editor | Date of Last Editor Review | Notes |
Lobular carcinoma in situ | Disease | ||||||||
Ductal carcinoma in situ | Disease | ||||||||
Invasive breast carcinoma of no special type | Disease | ||||||||
Microinvasive carcinoma | Disease | ||||||||
Invasive lobular carcinoma | Disease | ||||||||
Tubular carcinoma | Disease | ||||||||
Cribriform carcinoma | Disease | ||||||||
Mucinous carcinoma | Disease | ||||||||
Mucinous cystadenocarcinoma | Disease | ||||||||
Invasive micropapillary carcinoma | Disease | ||||||||
Disease | Page Type | Author | Date Assigned to Author | Target Completion Date | Author Content (Pending or Complete) | Date Completed by Author | Associate Editor | Date of Last Editor Review | Notes |
Carcinoma with apocrine differentiation | Disease | ||||||||
Metaplastic carcinoma | Disease | ||||||||
Acinic cell carcinoma | Disease | Patricija Zot | 2/28/2024 | PENDING | Katherine Geiersbach | ||||
Adenoid cystic carcinoma | Disease | Katherine Geiersbach / Jun Liao | 10/12/02022 | 11/11/2023 | COMPLETE | Hui Chen / Katherine Geiersbach | 12/6/2023 | 2021 template added | |
Secretory carcinoma | Disease | Hui Chen / Morteza Seifi | 10/12/2022 | 11/11/2023 | COMPLETE | Katherine Geiersbach | 2021 template added | ||
Mucoepidermoid carcinoma | Disease | ||||||||
Polymorphous adenocarcinoma | Disease | ||||||||
Tall cell carcinoma with reversed polarity | Disease | H. Evin Gulbahce | 8/11/2023 | 10/11/2023 | COMPLETE | Katherine Geiersbach | 2021 template added | ||
Neuroendocrine tumour | Disease | ||||||||
Neuroendocrine carcinoma | Disease | ||||||||
Disease | Page Type | Author | Date Assigned to Author | Target Completion Date | Author Content (Pending or Complete) | Date Completed by Author | Associate Editor | Date of Last Editor Review | Notes |
CHAPTER 3 (FIBROEPITHELIAL TUMOURS AND HAMARTOMAS OF THE BREAST) |
|
|
|
|
|
|
|
|
|
Hamartoma | Disease | ||||||||
Fibroadenoma | Disease | H. Evin Gulbahce / Patricija Zot | 8/11/2023 | 11/11/2023 | PENDING | 2021 template added | |||
Phyllodes tumour | Disease | Emilie Lalonde / H. Evin Gulbahce /Katherine Geiersbach | 8/11/2023 | 11/11/2023 | COMPLETE | 2021 template added | |||
CHAPTER 4 (TUMOURS OF THE NIPPLE) |
|
|
|
|
|
|
|
|
|
Syringomatous tumour | Disease | ||||||||
Nipple adenoma | Disease | ||||||||
Paget disease of the breast | Disease | ||||||||
CHAPTER 5 (MESENCHYMAL TUMOURS OF THE BREAST) |
|
|
|
|
|
|
|
|
|
Haemangioma | Disease | ||||||||
Disease | Page Type | Author | Date Assigned to Author | Target Completion Date | Author Content (Pending or Complete) | Date Completed by Author | Associate Editor | Date of Last Editor Review | Notes |
Angiomatosis | Disease | ||||||||
Atypical vascular lesions | Disease | ||||||||
Postradiation angiosarcoma of the breast | Disease | ||||||||
Primary angiosarcoma of the breast | Disease | ||||||||
Nodular fasciitis | Disease | ||||||||
Myofibroblastoma | Disease | ||||||||
Desmoid fibromatosis | Disease | ||||||||
Inflammatory myofibroblastic tumour | Disease | Yajuan Liu | 8/11/2023 | 11/11/2023 | COMPLETE | Katherine Geiersbach | 12/6/2023 | 2021 template added | |
Schwannoma | Disease | ||||||||
Neurofibroma | Disease | ||||||||
Disease | Page Type | Author | Date Assigned to Author | Target Completion Date | Author Content (Pending or Complete) | Date Completed by Author | Associate Editor | Date of Last Editor Review | Notes |
Granular cell tumour | Disease | ||||||||
Leiomyoma | Disease | ||||||||
Leiomyosarcoma | Disease | ||||||||
Lipoma | Disease | ||||||||
Angiolipoma | Disease | ||||||||
Liposarcoma | Disease | ||||||||
Pseudoangiomatous stromal hyperplasia | Disease | ||||||||
CHAPTER 6 (HAEMATOLYMPHOID TUMOURS OF THE BREAST) |
|
|
|
|
|
|
|
|
|
Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) | Disease | ||||||||
Follicular lymphoma | Disease | ||||||||
Disease | Page Type | Author | Date Assigned to Author | Target Completion Date | Author Content (Pending or Complete) | Date Completed by Author | Associate Editor | Date of Last Editor Review | Notes |
Diffuse large B-cell lymphoma | Disease | ||||||||
Burkitt lymphoma | Disease | ||||||||
Breast implant-associated anaplastic large cell lymphoma | Disease | ||||||||
CHAPTER 7 (TUMOURS OF THE MALE BREAST) |
|
|
|
|
|
|
|
|
|
Gynaecomastia | Disease | ||||||||
Carcinoma in situ | Disease | ||||||||
Invasive carcinoma | Disease | ||||||||
Metastases to the breast | Disease | ||||||||
CHAPTER 8 (GENETIC TUMOUR SYNDROMES OF THE BREAST) |
|
|
|
|
|
|
|
|
|
BRCA1/2-associated hereditary breast and ovarian cancer syndrome | Disease | See GTS5 volunteer sheet for authorship status | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Disease | Page Type | Author | Date Assigned to Author | Target Completion Date | Author Content (Pending or Complete) | Date Completed by Author | Associate Editor | Date of Last Editor Review | Notes |
Cowden syndrome | Disease | See DIG5 volunteer sheet for authorship status | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Ataxia-telangiectasia | Disease | See GTS5 volunteer sheet for authorship status | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Li-Fraumeni syndrome, TP53-associated | Disease | See GTS5 volunteer sheet for authorship status | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Li-Fraumeni syndrome, CHEK2-associated | Disease | See GTS5 volunteer sheet for authorship status | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
CDH1-associated breast cancer | Disease | See GTS5 volunteer sheet for authorship status | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
PALB2-associated cancers | Disease | See GTS5 volunteer sheet for authorship status | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Peutz-Jeghers syndrome | Disease | See GTS5 volunteer sheet for authorship status | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Neurofibromatosis type 1 | Disease | See GTS5 volunteer sheet for authorship status | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Polygenic component of breast cancer susceptibility | Disease | Xiaolin Hu | 6/4/2024 | Template added (6/4/24) |